CTLA4 and melanoma: To validate the ICR/GIE stratification, we assembled a cohort of 83 melanoma cases treated with ICI, either anti-CTLA4 or -PD-1, from previous published studies5,50,51 for which TMB, neoantigen load and gene expression were available.